Neurotech International (CHIA:NTI) - Cotización, noticias y análisis

Resumen de acción NTI

Neurotech International Limited, junto con sus filiales, se dedica a la investigación, diseño, desarrollo y fabricación de dispositivos y soluciones médicas en Australia.

Acerca de la empresa

NTI fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Análisis de riesgos

Los beneficios han disminuido un 10.5% al año en los últimos 5 años

No tiene una capitalización de mercado significativa (A$84M)

Los accionistas han sido diluidos en el último año

No tiene ingresos significativos (A$3M)

Competidores de Neurotech International Limited

Micro-X

ASX:MX1

AU$50.4m

EMVision Medical Devices

ASX:EMV

AU$170.0m

Austco Healthcare

ASX:AHC

AU$63.9m

Nova Eye Medical

ASX:EYE

AU$59.5m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Neurotech International
Historical stock prices
Current Share Price	AU$0.074
52 Week High	AU$0.13
52 Week Low	AU$0.032
Beta	1.83
1 Month Change	-29.52%
3 Month Change	-23.71%
1 Year Change	45.10%
3 Year Change	27.59%
5 Year Change	516.67%
Change since IPO	-69.80%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	NTI	AU Medical Equipment	Mercado AU
7D	-16.9%	0.5%	1.5%
1Y	45.1%	15.9%	7.4%

Rentabilidad vs. Industria: NTI superó al sector Australian Medical Equipment , que obtuvo un rendimiento del 14.7% el año pasado.

Rentabilidad vs. Mercado: NTI superó al mercado Australian, que obtuvo un rendimiento del 3.9% el año pasado.

Volatilidad de los precios

Is NTI's price volatile compared to industry and market?
NTI volatility
NTI Average Weekly Movement	11.1%
Medical Equipment Industry Average Movement	10.0%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.2%
10% least volatile stocks in AU Market	3.5%

Precio estable de las acciones: El precio de las acciones de NTI ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de NTI (11%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2016	n/a	Peter James Griffiths	www.neurotechinternational.com

Neurotech International Limited, junto con sus filiales, se dedica a la investigación, diseño, desarrollo y fabricación de dispositivos y soluciones médicas en Australia. La empresa se centra en el desarrollo y la comercialización de la plataforma Mente, una tecnología de plataforma para monitorizar y desempeñar un papel en las terapias a domicilio. Sus productos incluyen Mente Autism para el diagnóstico y tratamiento del autismo.

Resumen de fundamentos de Neurotech International Limited

¿Cómo se comparan los beneficios e ingresos de Neurotech International con su capitalización de mercado?
Estadísticas fundamentales de NTI
Capitalización bursátil	AU$75.29m
Beneficios(TTM)	-AU$4.98m
Ingresos (TTM)	AU$3.20m

23.5x

Ratio precio-ventas (PS)

-15.1x

Ratio precio-beneficio (PE)

¿Está NTI sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de NTI
Ingresos	AU$3.20m
Coste de los ingresos	AU$28.87k
Beneficio bruto	AU$3.18m
Otros gastos	AU$8.16m
Beneficios	-AU$4.98m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.0049
Margen bruto	99.10%
Margen de beneficio neto	-155.47%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado NTI a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción NTI

Recompensas

Análisis de riesgos

Competidores de Neurotech International Limited

ASX:MX1

AU$50.4m

ASX:EMV

AU$170.0m

ASX:AHC

AU$63.9m

ASX:EYE

AU$59.5m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Less than half of directors are independent

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited to Report Q1, 2024 Results on Oct 27, 2023

Neurotech International Limited, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.005 loss in FY 2022)

Recent updates

Less than half of directors are independent

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited to Report Q1, 2024 Results on Oct 27, 2023

Neurotech International Limited, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

Neurotech International Limited to Report Q4, 2023 Results on Jul 26, 2023

First half 2023 earnings released: AU$0.48 loss per share (vs AU$0.003 loss in 1H 2022)

Neurotech International Limited Announces First Patient Treated in Phase I/II PANDAS/PANS Trial

Neurotech International Limited Announces Approval for Additional Phase I/II ASD Trial Extension

Neurotech International Limited Receives HREC Approval for Phase I/II PANDAS/PANS Clinical Trial

Neurotech International Limited to Report Q3, 2023 Results on Jan 30, 2023

Neurotech International Limited Announces Grant of FDA Pre-IND Meeting for NTI164 in ASD

Neurotech International Limited Announces Passing of Professor Allan Cripps AO, Non-Executive Director

Neurotech International Limited Announces Commencement of Patient Randomisation and First Patient Successfully Treats Under New Phase II/III NTIASD2 Clinical Trial for Children with Autism Spectrum Disorder

Less than half of directors are independent

Neurotech International Limited, Annual General Meeting, Nov 30, 2022

Neurotech International Limited, Annual General Meeting, Nov 23, 2022

Neurotech International Limited Reports Further Significant Clinical Improvement at 20 Weeks for Paediatric Autism Patients Treated with NTI164

Neurotech International Limited Announces New Phase I/II Clinical Trial in Children with PANDAS/PANS

Neurotech International Limited Provides Autism Spectrum Disorder Phase I/II Clinical Trial Update

Less than half of directors are independent

Neurotech International Limited Announces Transition of Alexandra Andrews from Chief Executive Officer to a New Position of Chief Operating Officer

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.015 loss in FY 2021)

Neurotech International Limited Announces Currently Finalising a Pivotal Phase II/III Clinical Trial Design to be Conducted in Australia

Neurotech International ORDINARY FULLY PAID to Be Deleted from OTC Equity

Neurotech International Limited Announces Executive Changes

Neurotech International Limited Announces Results with NTI164 in Paediatric ASD

High number of new directors

Neurotech International Limited Announces Important Developments Relating to the Study Protocol Assessing NTI164 in Children with Autism Spectrum Disorder

High number of new directors

Neurotech International Limited Announces Successful Developments Relating to Safety and Tolerability of NTI164 and Key Behavioural Parameters That Impact Autism Spectrum Disorder Patients

Neurotech International Limited Appoints Alexandra Andrews as Chief Executive Officer, Effective 8 March 2022

Neurotech International Limited Announces Nti164 Clinical Program Update

Full year 2021 earnings released: AU$0.015 loss per share (vs AU$0.011 loss in FY 2020)

Neurotech International Limited Announces the Continuation of Its Pre-Clinical Program in Neuro-Inflammatory Disease Models In-Line with Research and Development Pathway

Neurotech International Limited Initiates Phase I/II Open Label Study into Autism

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2 million.

Neurotech International Limited Announces Strategic Cultivation Partnership with CannaPacific Limited

Neurotech International Limited Announces the Expansion of Its Exclusive License with Dolce Cann Global Pty Ltd

Neurotech International Limited Provides an Update on Clinical Study Program

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Neurotech International Limited Announces Initiation of Clinical Product Formulation Studies

Neurotech International Limited Announces Transition of Peter Griffiths as CEO

Neurotech International Limited Commences Landmark in Vitro Trials of Unique Cannabis Strains

Full year earnings released - AU$0.011 loss per share

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Neurotech International Limited

23.5x

-15.1x

Beneficios e Ingresos